PathFinderTG® is a patented advanced testing platform for resolving “indeterminate, atypical, suspicious, equivocal and non-diagnostic specimen” diagnoses from the original pathology specimen.  PathFinderTG integrates the power of quantitative genetic mutational analysis with the intelligence of pathology to deliver unprecedented diagnostic accuracy when differentiating between:

• Reactive versus neoplastic lesions
• Grade of dysplasia
• Benign versus malignant lesions
• Metastatic, synchronous and recurrent tumors
• Biologically indolent versus aggressive tumors

When “indeterminate” is the only available diagnosis using traditional pathology methods, PathFinderTG delivers critical information from which your doctor can develop the most effective personalized treatment plan.  Depending on the tumor type, PathFinderTG provides the earliest possible information for treatment decisions including the use of:

• Surgery
• Chemotherapy
• Radiation therapy
• Interval for re-evaluating "indeterminate" and benign tumors

PathFinderTG focuses on acquired mutational damage rather than inherited genetic predisposition for certain diseases, although there are certain NIH recommended inherited conditions for which we do test.  There are 500+ peer reviewed publications underpinning the science behind PathFinderTG and 129+ peer reviewed papers specifically supporting the clinical effectiveness of Topographic Genotyping™, also known as PathFinderTG. 

In fact, it has been reported in peer reviewed medical journals that the temporal sequence of acquired mutational damage revealed by the PathFinderTG test is an earlier demonstration of tumor biological aggressiveness than current staging systems that rely on the depth of invasion already achieved by the tumor.  PathFinderTG studies have demonstrated that biologic aggressiveness and metastasis are a function of acquired mutational damage, not tumor invasiveness at the primary cancer site.  This distinction has dramatic implications for cancer treatment planning and is only available in the context of the temporal sequence of acquired mutational damage that PathFinderTG reveals.

RedPath works with your doctor and the pathologist to provide the most accurate diagnostic information available today.  Depending upon the diagnostic question, organ and specimen type, Topographic Genotyping is reported in major peer reviewed journals as having accuracy rates of 82% to 100%.  In each instance, RedPath delivers unprecedented diagnostic accuracy compared to current standards of care.